OncoMatch/Clinical Trials/NCT03280511
Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients
Is NCT03280511 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies PIPAC for peritoneum cancer.
Treatment: PIPAC — In this study, patients will be offered two Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) treatments with oxaliplatin after primary resection and standard adjuvant chemotherapy (if indicated) for colon cancer. Furthermore, the study will explore, whether it is possible to find free intraperitoneal tumor cells (FITC) after resection and adjuvant chemotherapy for colon cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Ovarian Cancer
Colorectal Cancer
Disease stage
Required: Stage PT4NANYM0, PTANYNANYM1 (UICC 8th edition)
high-risk tumors defined as: perforated / pT4NanyM0 (UICC 8th edition) / pTanyNanyM1 with radically resected PM including ovarian metastases
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: cytoreductive surgery with hipec
Lab requirements
Blood counts
anc > 1.5 x 10^9/l and platelets > 100 x 10^9/l
Kidney function
gfr >= 50 ml/min (cockcroft-gault equation)
Liver function
bilirubin < 1.5 x unl
Cardiac function
nyha class <= 2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT03280511 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior cytoreductive surgery with hipec disqualifies patients from enrollment.
What disease stage is eligible?
Stage PT4NANYM0 or PTANYNANYM1 is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages